Triggering receptor expressed on myeloid cells in the pathogenesis of periodontitis: potential novel treatment strategies

Courtney P. Rudick, Takanari Miyamoto, Melissa S. Lang, Devendra K. Agrawal

Research output: Contribution to journalReview article

Abstract

Introduction: Periodontal diseases are polymicrobial inflammatory disorders of the tissue, ligament, and bone structures supporting teeth. Periodontitis (inflammation with corresponding loss of attachment) affects 40–50% of adults. Recently, members of the Triggering Receptor on Myeloid Cell (TREM) family have been studied to determine their relationship to these diseases. Areas covered: TREM-1 is a receptor expressed on the surface of PMNs, monocytes, macrophages, dendritic cells, vascular smooth muscle cells, and keratinocytes upregulated in the presence of periodontal inflammation. TREM-1 expression can be upregulated by oral bacterium Porphyromonas gingivalis that can be abrogated by a sub-antimicrobial dose of doxycycline. When cleaved from the cell surface, a soluble form of TREM-1 (sTREM-1) can be used as a biomarker of inflammation and might also provide a link between oral and systemic inflammation. While less understood, TREM-2 has a role in osteoclastogenesis which could contribute to the alveolar bone destruction seen in more advanced periodontitis. Expert commentary: Additional studies to simulate biofilm microenvironment in TREM research are warranted. Longitudinal studies determining TREM-1, sTREM-1, and TREM-2 levels in tissues over time and progression of periodontal diseases would provide valuable information in the role of TREM receptors as indicators of or contributors to the disease process.

Original languageEnglish (US)
Pages (from-to)1189-1197
Number of pages9
JournalExpert Review of Clinical Immunology
Volume13
Issue number12
DOIs
StatePublished - Dec 2 2017

Fingerprint

Periodontitis
Myeloid Cells
Inflammation
Periodontal Diseases
Bone and Bones
Periodontium
Porphyromonas gingivalis
Doxycycline
Biofilms
Keratinocytes
Vascular Smooth Muscle
Ligaments
Osteogenesis
Dendritic Cells
Smooth Muscle Myocytes
Longitudinal Studies
Monocytes
Biomarkers
Macrophages
Bacteria

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Triggering receptor expressed on myeloid cells in the pathogenesis of periodontitis : potential novel treatment strategies. / Rudick, Courtney P.; Miyamoto, Takanari; Lang, Melissa S.; Agrawal, Devendra K.

In: Expert Review of Clinical Immunology, Vol. 13, No. 12, 02.12.2017, p. 1189-1197.

Research output: Contribution to journalReview article

@article{abc347ed010949ad9f5658b7a4f271a2,
title = "Triggering receptor expressed on myeloid cells in the pathogenesis of periodontitis: potential novel treatment strategies",
abstract = "Introduction: Periodontal diseases are polymicrobial inflammatory disorders of the tissue, ligament, and bone structures supporting teeth. Periodontitis (inflammation with corresponding loss of attachment) affects 40–50{\%} of adults. Recently, members of the Triggering Receptor on Myeloid Cell (TREM) family have been studied to determine their relationship to these diseases. Areas covered: TREM-1 is a receptor expressed on the surface of PMNs, monocytes, macrophages, dendritic cells, vascular smooth muscle cells, and keratinocytes upregulated in the presence of periodontal inflammation. TREM-1 expression can be upregulated by oral bacterium Porphyromonas gingivalis that can be abrogated by a sub-antimicrobial dose of doxycycline. When cleaved from the cell surface, a soluble form of TREM-1 (sTREM-1) can be used as a biomarker of inflammation and might also provide a link between oral and systemic inflammation. While less understood, TREM-2 has a role in osteoclastogenesis which could contribute to the alveolar bone destruction seen in more advanced periodontitis. Expert commentary: Additional studies to simulate biofilm microenvironment in TREM research are warranted. Longitudinal studies determining TREM-1, sTREM-1, and TREM-2 levels in tissues over time and progression of periodontal diseases would provide valuable information in the role of TREM receptors as indicators of or contributors to the disease process.",
author = "Rudick, {Courtney P.} and Takanari Miyamoto and Lang, {Melissa S.} and Agrawal, {Devendra K.}",
year = "2017",
month = "12",
day = "2",
doi = "10.1080/1744666X.2017.1392855",
language = "English (US)",
volume = "13",
pages = "1189--1197",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Triggering receptor expressed on myeloid cells in the pathogenesis of periodontitis

T2 - potential novel treatment strategies

AU - Rudick, Courtney P.

AU - Miyamoto, Takanari

AU - Lang, Melissa S.

AU - Agrawal, Devendra K.

PY - 2017/12/2

Y1 - 2017/12/2

N2 - Introduction: Periodontal diseases are polymicrobial inflammatory disorders of the tissue, ligament, and bone structures supporting teeth. Periodontitis (inflammation with corresponding loss of attachment) affects 40–50% of adults. Recently, members of the Triggering Receptor on Myeloid Cell (TREM) family have been studied to determine their relationship to these diseases. Areas covered: TREM-1 is a receptor expressed on the surface of PMNs, monocytes, macrophages, dendritic cells, vascular smooth muscle cells, and keratinocytes upregulated in the presence of periodontal inflammation. TREM-1 expression can be upregulated by oral bacterium Porphyromonas gingivalis that can be abrogated by a sub-antimicrobial dose of doxycycline. When cleaved from the cell surface, a soluble form of TREM-1 (sTREM-1) can be used as a biomarker of inflammation and might also provide a link between oral and systemic inflammation. While less understood, TREM-2 has a role in osteoclastogenesis which could contribute to the alveolar bone destruction seen in more advanced periodontitis. Expert commentary: Additional studies to simulate biofilm microenvironment in TREM research are warranted. Longitudinal studies determining TREM-1, sTREM-1, and TREM-2 levels in tissues over time and progression of periodontal diseases would provide valuable information in the role of TREM receptors as indicators of or contributors to the disease process.

AB - Introduction: Periodontal diseases are polymicrobial inflammatory disorders of the tissue, ligament, and bone structures supporting teeth. Periodontitis (inflammation with corresponding loss of attachment) affects 40–50% of adults. Recently, members of the Triggering Receptor on Myeloid Cell (TREM) family have been studied to determine their relationship to these diseases. Areas covered: TREM-1 is a receptor expressed on the surface of PMNs, monocytes, macrophages, dendritic cells, vascular smooth muscle cells, and keratinocytes upregulated in the presence of periodontal inflammation. TREM-1 expression can be upregulated by oral bacterium Porphyromonas gingivalis that can be abrogated by a sub-antimicrobial dose of doxycycline. When cleaved from the cell surface, a soluble form of TREM-1 (sTREM-1) can be used as a biomarker of inflammation and might also provide a link between oral and systemic inflammation. While less understood, TREM-2 has a role in osteoclastogenesis which could contribute to the alveolar bone destruction seen in more advanced periodontitis. Expert commentary: Additional studies to simulate biofilm microenvironment in TREM research are warranted. Longitudinal studies determining TREM-1, sTREM-1, and TREM-2 levels in tissues over time and progression of periodontal diseases would provide valuable information in the role of TREM receptors as indicators of or contributors to the disease process.

UR - http://www.scopus.com/inward/record.url?scp=85034431922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034431922&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2017.1392855

DO - 10.1080/1744666X.2017.1392855

M3 - Review article

C2 - 29027827

AN - SCOPUS:85034431922

VL - 13

SP - 1189

EP - 1197

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 12

ER -